Exact Sciences Corp (OQ:EXAS)

Apr 15, 2024 06:00 am ET
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
Apr 11, 2024 06:00 am ET
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a new series of 1.75% Convertible Senior Notes due 2031 (the “New Notes”) in exchange for (i) the retirement of $359.7 million aggrega
Apr 08, 2024 12:05 pm ET
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening. ASCEND-2 is a large, multi-center, prospective, ca
Apr 08, 2024 06:00 am ET
Exact Sciences Schedules First Quarter 2024 Earnings Call
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Apr 04, 2024 06:05 am ET
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with
Mar 28, 2024 06:00 am ET
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing were recently published in the
Mar 27, 2024 08:05 am ET
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world.
Mar 13, 2024 05:03 pm ET
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue.
Mar 07, 2024 07:59 am ET
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society recommendations.2
Feb 26, 2024 06:00 am ET
Exact Sciences to Participate in March Investor Conference
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Feb 21, 2024 04:05 pm ET
Exact Sciences Announces Fourth Quarter 2023 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.
Feb 01, 2024 06:00 am ET
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Jan 07, 2024 03:30 pm ET
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA
Jan 02, 2024 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Dec 07, 2023 07:05 am ET
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
MADISON, Wis., Dec. 7, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations.
Nov 30, 2023 03:05 pm ET
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimatesNew concordance analysis supporting the generation of Oncotype DX® results from core needle biopsy to personalize treatment decisionsADAPTcycle trial data, using Oncotype DX results and endocrine response to stratify patients, may expand the number of breast cancer patients able to forgo chemotherapy post-surgery; data chosen as late-breaking abstractProspective trial data regarding the potential omission of radiation therapy after sur
Nov 17, 2023 06:10 am ET
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test
Nov 01, 2023 04:05 pm ET
Exact Sciences Announces Third-Quarter 2023 Results
Reports record revenue, delivers more than a million test results, raises full-year guidance
Nov 01, 2023 06:00 am ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Oct 22, 2023 03:00 pm ET
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG
Oct 20, 2023 06:05 pm ET
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24, in Madrid, Spain.
Oct 09, 2023 06:00 am ET
Exact Sciences schedules third quarter 2023 earnings call
MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Oct 09, 2023 05:58 am ET
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking data on next-generation Cologuard® from the BLUE-C pivotal trial during the American College of Gastroenterology (ACG) Annual Meeting, taking place October 20-25, 2023, in Vancouver, Canada. Further evidence supporting both the cost-effectiveness of Cologuard and performance of next-generation Cologuard will also be presented at the annual meeting. ACG has made abstracts available on their website.
Sep 12, 2023 08:35 am ET
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.
Aug 01, 2023 04:05 pm ET
Exact Sciences Announces Second-Quarter 2023 Results
Reports record results, generates positive free cash flow, raises full-year guidance
Jul 10, 2023 06:00 am ET
Exact Sciences schedules second quarter 2023 earnings call
MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Jun 21, 2023 09:31 am ET
Thinking about trading options or stock in Tesla, Microsoft, Exact Sciences, Coinbase Global, or Logitech International?
NEW YORK, June 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, MSFT, EXAS, COIN, and LOGI.
Jun 21, 2023 07:14 am ET
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research
Jun 20, 2023 04:05 pm ET
Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening
BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity
Jun 01, 2023 08:00 am ET
EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™
Award marks fifth consecutive year company has received prestigious distinction
Jun 01, 2023 06:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
May 26, 2023 06:58 am ET
Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023
Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2Surveillance, Epidemiology, and End Results (SEER) program analysis shows continued, long-term confidence in prognostic value of the Oncotype DX Breast Recurrence Score® 3 New modeling data show superior health outcomes in colorectal cancer screening with Cologuard® compared to blood-based tests, including lower mortality and more life-years gained4,5 MADISON, Wis., May 26, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cance
May 17, 2023 07:00 am ET
EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS
MADISON, Wis., May 17, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.1 million to 18 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people who are medically underserved.
May 09, 2023 04:05 pm ET
Exact Sciences Announces First Quarter 2023 Results
Reports record results, raises full-year guidance, accelerates path to positive free cash flow
May 09, 2023 06:37 am ET
Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting
Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard® is more effective when compared to hypothetical blood-based screening1-3
May 01, 2023 06:00 am ET
Exact Sciences to participate in May investor conference
MADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Apr 12, 2023 03:07 pm ET
Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting
Research from Exact Sciences' multi-cancer early detection (MCED) program supports advanced imaging as an optimal and potentially more efficient strategy for identifying cancerous tumor location following a positive MCED test result1 Exact Sciences presents preliminary data showing promise of molecular residual disease (MRD) detection technologies for detection of cancer recurrence post therapy2MADISON, Wis., April 12, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighti
Apr 10, 2023 06:00 am ET
Exact Sciences schedules first quarter 2023 earnings call
MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Feb 23, 2023 08:29 am ET
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 Notes") and certain of its 0.3750% Convertible Senior Notes due 2028 (the "Existing 2028 Notes", and together with the "Existing 2027 Notes", the "Existing Notes"). Pursuant to the Agreement, the Company
Feb 07, 2023 07:29 am ET
Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer
Feb 01, 2023 05:00 am ET
Exact Sciences schedules fourth quarter 2022 earnings call
MADISON, Wis., Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Jan 20, 2023 08:36 am ET
Thinking about trading options or stock in Microsoft, Tesla, Roku, Alphabet, or Exact Sciences?
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, TSLA, ROKU, GOOGL, and EXAS.
Jan 09, 2023 08:31 am ET
Thinking about trading options or stock in Exact Sciences, Futu Holdings, Tesla, Five Below, or NVIDIA?
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAS, FUTU, TSLA, FIVE, and NVDA.
Jan 08, 2023 02:45 pm ET
Jan 03, 2023 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 3, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Dec 20, 2022 09:13 am ET
Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test
MADISON, Wis., Dec. 20, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, supports recent policy changes that help increase access to recommended non-invasive colorectal cancer screening tests. These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient. For most patients, these financial protections take effect starting January 1, 2023.
Dec 16, 2022 08:31 am ET
Thinking about trading options or stock in Exact Sciences, Alibaba, Winnebago, Apple, or Etsy?
NEW YORK, Dec. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAS, BABA, WGO, AAPL, and ETSY.
Dec 09, 2022 09:05 am ET
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients
MADISON, Wis., Dec. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®). The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
Dec 06, 2022 03:05 pm ET
Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022
New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score® test, the only genomic test to predict chemotherapy benefit in early-stage breast cancer patients 1,2,3,4Initial validation study of a new test to predict radiotherapy benefit will be highlighted in the official SABCS press program, demonstrating Exact Sciences' commitment to supporting patients throughout cancer treatmentMADISON, Wis., Dec. 6, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic
Nov 03, 2022 04:05 pm ET
Exact Sciences Announces Third Quarter 2022 Results
Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
Nov 01, 2022 06:00 am ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Oct 24, 2022 07:33 am ET
Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting
Data presentations include positive impact of eliminating patient cost for follow-up colonoscopies, shifting to non-invasive colorectal cancer testing, and increasing overall screening as 900 deaths averted per 1 million people screened
Oct 10, 2022 06:00 am ET
Exact Sciences schedules third quarter 2022 earnings call
MADISON, Wis., Oct. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Sep 10, 2022 04:33 am ET
Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress
Multi-Biomarker Approach Achieves 61 Percent Sensitivity for Cancer at an Overall Specificity of 98.2 Percent in Robust Case-Control Study Including Nearly 600 Cancer Samples
Sep 01, 2022 06:00 am ET
Exact Sciences to participate in September investor conference
MADISON, Wis., Sept. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Aug 02, 2022 04:05 pm ET
Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals
Aug 02, 2022 04:05 pm ET
Aug 01, 2022 06:00 am ET
Exact Sciences to participate in August investor conference
MADISON, Wis., Aug. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jun 21, 2022 06:00 am ET
Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs
NEWARK, Calif. and MADISON, Wis., June 21, 2022 /PRNewswire/ -- Ultima Genomics, Inc. and Exact Sciences Corporation (Nasdaq: EXAS) have entered a long-term supply agreement for Ultima's next-generation sequencing (NGS) technologies. Under the terms of the supply agreement, Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other commercially available technologies. The companies also plan to develop one or more of Exact Sciences' advanced cancer diagnostic tests using Ultima's sequencing t
May 27, 2022 08:50 am ET
Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022
MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago, Illinois.
May 27, 2022 06:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
May 02, 2022 06:00 am ET
Exact Sciences to participate in May investor conference
MADISON, Wis., May 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Apr 28, 2022 09:00 am ET
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxPONDER study, recently published in The New England Journal of Medicine MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its
Apr 26, 2022 04:05 pm ET
Exact Sciences Announces First Quarter 2022 Results
Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing revenue of $27MTotal first quarter revenue, excluding COVID-19 testing, increased 24% compared to the first quarter of 2021, including 28% increase in Screening revenue and 18% increase in Precision Oncology revenueScreening revenue growth driven by improved sales team productivity, Cologuard rescreens, and Cologuard use in 45-49 age groupMADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics,
Apr 08, 2022 06:00 am ET
Exact Sciences schedules first quarter 2022 earnings call
MADISON, Wis., April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 financial results after the close of the U.S. financial markets on April 26, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Mar 07, 2022 08:00 am ET
Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
NEW YORK and MADISON, Wis., March 7, 2022 /PRNewswire/ -- Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, today announced she has teamed up with Exact Sciences (NASDAQ: EXAS), the maker of Cologuard®, to highlight the urgent need for people to get screened.
Mar 01, 2022 08:30 am ET
Diversey Appoints Katherine S. Zanotti to its Board of Directors
Diversey Holdings, Ltd. (NASDAQ: DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company’s board of directors, effective March 1, 2022. This appointment will bring the...
Feb 28, 2022 05:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., Feb. 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Feb 22, 2022 03:05 pm ET
Exact Sciences Announces Fourth Quarter 2021 Results
MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31, 2021.
Feb 08, 2022 05:00 am ET
Exact Sciences schedules fourth quarter 2021 earnings call
MADISON, Wis., Feb. 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Feb 01, 2022 05:00 am ET
Exact Sciences to participate in February investor conferences
MADISON, Wis., Feb. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
Jan 31, 2022 10:00 am ET
Thinking about trading options or stock in Chevron, Caterpillar, Citrix Systems, Charles Schwab, or EXACT Sciences?
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVX, CAT, CTXS, SCHW, and EXAS.
Jan 18, 2022 04:01 pm ET
Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
MADISON, Wis., Jan. 18, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at specificity of 92.4% for negative samples confirmed by colonoscopy. Subgroup analyses showed 83.3% sensitivity for high-grade dysplasia, the most dangerous precancerous lesions, and 57.2% for all advanced precancerous lesions. These data will be presented January 22 at ASCO GI in a poster titled, "Second-generation Multi-target Stool DNA Panel Reliab
Jan 09, 2022 06:00 pm ET
Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
MADISON, Wis., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) announced today it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases.
Jan 09, 2022 06:00 pm ET
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
MADISON, Wis., and WALTHAM, Mass., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and OncXerna Therapeutics, Inc., a precision medicine company, announced today they have entered an exclusive license agreement to bring OncXerna's Xerna TME Panel lab services to more U.S. patients. The Xerna TME (tumor microenvironment) Panel is an innovative gene expression score that helps identify patients likely to respond to anti-angiogenic and immunotherapies. The agreement allows Exact Sciences to provide more critical answers to cancer patients and physicians facing difficult therapy
Jan 09, 2022 06:00 pm ET
Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
MADISON, Wis., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $472 million and $475 million for the fourth quarter ended Dec. 31, 2021.
Jan 03, 2022 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that company management will participate in the following virtual conference and invited investors to participate by webcast.
Dec 08, 2021 10:30 am ET
New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making
MADISON, Wis., Dec. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented at the meeting include an oral presentation of updated data from the RxPONDER study led by the independent SWOG Cancer Research Network, and sponsored by the National Cancer Institute (NCI).
Dec 01, 2021 04:05 pm ET
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
Dec 01, 2021 04:05 pm ET
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
Nov 23, 2021 08:08 am ET
New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
MADISON, Wis., Nov. 23, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for risk-assessment in clinically low-risk prostate cancer patients.1 Published in Urologic Oncology: Seminars and Original Investigations and led by study collaborators at the Cleveland Clinic, the findings showed that men who were discovered to have adverse pathology, following a radical prostatectomy, were 10 times more likely to develop metast
Nov 18, 2021 07:30 am ET
Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection
MADISON, Wis. and PHILADELPHIA, Nov. 18, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims to evaluate MCED test safety and efficacy and help determine how to facilitate the implementation of effective MCED testing in the future. 
Nov 04, 2021 08:14 am ET
Section 32 Raises $740 Million Venture Fund
SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the app
Nov 02, 2021 04:05 pm ET
Exact Sciences announces third quarter 2021 results
MADISON, Wis., Nov. 2, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020.
Nov 01, 2021 06:00 am ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Oct 25, 2021 05:33 pm ET
New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening
MADISON, Wis., Oct. 25, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer (CRC) compared to annual fecal immunochemical test (FIT), when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population. Cologuard remained cost-effective in all the real-world adherence scenarios modeled. The modeling analyses were consistent
Oct 08, 2021 06:00 am ET
Exact Sciences schedules third quarter 2021 earnings call
MADISON, Wis., Oct. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Sep 01, 2021 06:00 am ET
Exact Sciences to participate in September investor conferences
MADISON, Wis., Sept. 1, 2021  /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
Aug 30, 2021 07:00 am ET
Renalytix Appoints Daniel J. Levangie to its Board of Directors
Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Company’s board of directors. Mr. Levangie is also appointed as a member of the Company’s remuneration committee.   Mr. Levangie is an...
Aug 16, 2021 06:00 am ET
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence Score® Program. The test helps guide chemotherapy treatment recommendations and provides risk of distant recurrence in patients with hormone receptor-positive, HER2-negative early-stage breast cancer with up to three positive lymph nodes. MHLW approval is a critical step in making Oncotype DX® accessible to breast cancer patients in Japan.
Aug 13, 2021 09:00 am ET
Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular Carcinoma
MADISON, Wis., Aug. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-reviewed journal Clinical Gastroenterology and Hepatology (CGH). The test delivers 82% early-stage sensitivity, and an overall 88% sensitivity and 87% specificity1 for the detection of hepatocellular carcinoma (HCC), the leading form of liver cancer.
Jul 28, 2021 04:05 pm ET
Exact Sciences Announces Second Quarter 2021 Results
MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020.
Jul 08, 2021 06:00 am ET
Exact Sciences schedules second quarter 2021 earnings call
MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. financial markets on July 28, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress.
Feb 22, 2021 05:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., Feb. 22, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
Feb 16, 2021 03:05 pm ET
Exact Sciences Announces Fourth Quarter 2020 Results
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.
Feb 16, 2021 03:05 pm ET
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope's Genomics Institute, TGen
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sc
Feb 16, 2021 08:31 am ET
Thinking about trading options or stock in Nvidia, General Electric, Nio, EXACT Sciences, or Paypal?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, GE, NIO, EXAS, and PYPL.
Feb 01, 2021 05:00 am ET
Exact Sciences schedules fourth quarter 2020 earnings call
MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. EST to discuss financial results and business progress.
Feb 01, 2021 05:00 am ET
Exact Sciences to participate in February investor conferences
MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Jan 13, 2021 01:45 pm ET
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
MADISON, Wis., Jan. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
Jan 12, 2021 01:45 pm ET
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
MADISON, Wis., Jan. 12, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research, that expands on foundational clinical study findings to include a key younger population. Study results show that among average-risk adults between the ages of 45 and 49 Cologuard® (mt-sD­­­­NA) demonstrated test specificity of 95.2% in participants with non-advanced precancerous lesions or negative findings at colonoscopy and 96.3% in only those with negative colonoscopy findings. These analy
Jan 12, 2021 09:55 am ET
Should you invest in Exxon Mobil, Wells Fargo, General Motors, Etsy, or EXACT Sciences?
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XOM, WFC, GM, ETSY, and EXAS.
Jan 10, 2021 06:30 pm ET
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
MADISON, Wis., Jan. 10, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020.
Jan 05, 2021 07:25 am ET
Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening
MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive").
Dec 28, 2020 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Dec. 28, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
Dec 11, 2020 08:00 am ET
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS) building on the clinical value of the Oncotype DX Breast Recurrence Score® test. These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.
Dec 09, 2020 08:00 am ET
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium
Dec 09, 2020 08:00 am ET
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium
Nov 23, 2020 05:00 am ET
Exact Sciences to participate in December investor conference
MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
Nov 17, 2020 07:00 am ET
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
WASHINGTON, Nov. 17, 2020 /PRNewswire/ -- Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: EXAS), Foundation Medicine, Illumina (NASDAQ: ILMN), LabCorp (NYSE: LH), QIAGEN (NYSE: QGEN), Roche Diagnostics (SIX: RO, ROG: OTCQX: RHHBY), and Thermo Fisher Sc
Nov 02, 2020 05:00 am ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Oct 28, 2020 09:31 am ET
Thinking about buying stock in Apple, Titan Pharmaceuticals, Tupperware Brands, EXACT Sciences, or Roku?
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, TTNP, TUP, EXAS, and ROKU.
Oct 27, 2020 04:35 pm ET
Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released draft updated colorectal cancer screening guidelines recommending that screening begin at age 45, and including Exact Sciences' (NASDAQ: EXAS) Cologuard® (referred to in the draft guidelines as sDNA-FIT) as a recommended screening method for all average-risk patients between the ages of 45 and 75.
Oct 27, 2020 08:30 am ET
Thinking about buying stock in Xilinx, General Electric, EXACT Sciences, Harley-Davidson, or American International?
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XLNX, GE, EXAS, HOG, and AIG.
Oct 27, 2020 07:10 am ET
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its common stock, par value $0.01 per share, in a registered direct offering to ten institutional investors, including some of its largest shareholders as well as healthcare specialist firms Casdin Capital and Rock Springs Capital.
Oct 27, 2020 07:01 am ET
Exact Sciences Announces Third Quarter 2020 Results
MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.
Oct 27, 2020 07:00 am ET
Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close during the first quarter of 2021, subject to regulatory approval and the sa
Aug 03, 2020 06:00 am ET
Exact Sciences to participate in August investor conference
MADISON, Wis., Aug. 3, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jul 30, 2020 04:05 pm ET
Exact Sciences Announces Second Quarter 2020 Results
MADISON, Wis., July 30, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $268.9 million for the second quarter ended June 30, 2020, compared to $199.9 million for the same period of 2019.
Jul 08, 2020 06:00 am ET
Exact Sciences schedules annual meeting, second quarter 2020 earnings call
MADISON, Wis., July 8, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.
Jun 16, 2020 08:00 am ET
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
MADISON, Wis., June 16, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the publication of results highlighting the performance of the Oncotype DX Genomic Prostate Score® (GPS™) result in patients with unfavorable intermediate (UFI)-risk prostate cancer. Published in Urology, the new results demonstrate the GPS test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients.
May 29, 2020 08:00 am ET
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
MADISON, Wis., May 29, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced it is presenting new data at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program. These data further demonstrate the clinical value of the Oncotype DX Breast Recurrence Score® test and exemplify the research progress made by Exact Sciences' Mayo Clinic collaboration toward smarter solutions across the cancer continuum.
May 26, 2020 06:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., May 26, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
May 14, 2020 06:00 am ET
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
- Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with chemotherapy-sparing effect  
May 06, 2020 04:05 pm ET
Exact Sciences Announces First Quarter 2020 Results
MADISON, Wis., May 6, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $347.8 million for the first quarter ended Mar. 31, 2020, compared to $162.0 million for the same period of 2019.
May 05, 2020 10:30 am ET
New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods
MADISON, Wis., May 5, 2020 /PRNewswire/ -- New research from Exact Sciences Corp. (NASDAQ: EXAS) uses real-world-adjusted adherence rates in a colorectal cancer microsimulation, the Colorectal Cancer and Adenoma Incidence and Mortality model (CRC-AIM), to reinforce the value of Cologuard (mt-sDNA) as an effective colorectal cancer screening test. Cologuard offers significant advantages over the fecal immunochemical test (FIT) and real-world adherence data further highlights those advantages. Cologuard has higher sensitivity, a longer interval, and higher observed adherence rates in real-worl
May 04, 2020 06:00 am ET
Exact Sciences to participate in May investor conference
MADISON, Wis., May 4, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited investors to participate by webcast.
Apr 21, 2020 09:31 am ET
Thinking about trading options or stock in EXACT Sciences, FLIR Systems, Wayfair, Exxon Mobil, or Zoom Video Communications?
NEW YORK, April 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAS, FLIR, W, XOM, and ZM.
Apr 08, 2020 06:00 am ET
Exact Sciences schedules first-quarter 2020 earnings call
MADISON, Wis., April 8, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Apr 02, 2020 09:00 am ET
10x Genomics Appoints Kim Popovits to Board of Directors
10x Genomics, Inc. (Nasdaq: TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors.  She brings decades of experience in...
Apr 02, 2020 06:00 am ET
Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth
MADISON, Wis., April 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced it would be devoting significant patient education resources toward the ability to request Cologuard® online through a telehealth provider. During the COVID-19 pandemic, people are staying home to avoid spreading the virus. Telehealth offers a way to screen more people at home, even during a public health crisis.
Mar 20, 2020 09:31 am ET
Thinking about buying stock in EXACT Sciences, GenMark Diagnostics, SunLink Health Systems, Tyson Foods, or Slack Technologies?
NEW YORK, March 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAS, GNMK, SSY, TSN, and WORK.
Mar 19, 2020 06:00 am ET
Exact Sciences Takes Action during COVID-19 Pandemic
MADISON, Wis., March 19, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today provided an update on the actions it is taking to support patients, employees, and public health initiatives in response to the coronavirus (COVID-19) pandemic.
Nov 08, 2019 07:02 am ET
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
Nov 08, 2019 07:02 am ET
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
Nov 08, 2019 07:00 am ET
Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation
BOSTON, Nov. 8, 2019 /PRNewswire/ -- (NASDAQ: EXAS) – A new study of 443 patients by Exact Sciences Corp. and its collaborators demonstrated 80% sensitivity at 90% specificity with a novel combination of six blood-based biomarkers for the most common type of liver cancer, hepatocellular carcinoma (HCC)i. The study also showed 71% sensitivity for early stage HCC at 90% specificity. The study compared performance to the alpha-fetoprotein (AFP) test, which demonstrated 45% sensitivity at 90% specificity for early stage HCC. Lead author Naga Chalasani, M.D., Associate Dean for Clinical Research
Nov 07, 2019 12:55 pm ET
Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences
REDWOOD CITY, Calif., Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (NASDAQ: EXAS) at a special meeting held earlier today.
Nov 04, 2019 05:30 pm ET
Shenandoah Telecommunications Set to Join S&P SmallCap 600
NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Shenandoah Telecommunications Co. (NASD: SHEN) will replace Genomic Health Inc. (NASD: GHDX) in the S&P SmallCap 600 effective prior to the open of trading on Friday, November 8. Exact Sciences Corp. (NASD:EXAS) is acquiring Genomic Health in a transaction expected to be completed soon pending final conditions.
Nov 01, 2019 06:00 am ET
Exact Sciences to participate in November investor conferences
MADISON, Wis., Nov. 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.
Oct 29, 2019 04:05 pm ET
Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study
MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- (NASDAQ: EXAS) – Promising research from Exact Sciences Corp. and Mayo Clinic shows new methylation and protein markers detect colorectal cancer and advanced adenomas with high accuracy. Findings from the blinded, case-control study were presented at the American College of Gastroenterology's (ACG) 2019 Annual Scientific Meeting today. The study is part of an effort to increase specificity of Cologuard®, while maintaining its high level of sensitivity. Working in collaboration with Mayo Clinic, Exact Sciences has identified novel markers and impro
Oct 29, 2019 04:05 pm ET
Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million
MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $218.8 million and screened approximately 456,000 people with Cologuard during the quarter ended September 30, 2019. Third-quarter 2019 revenue and test volume grew 85 percent and 89 percent, respectively, from the same period of 2018.
Oct 17, 2019 10:57 am ET
Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm
NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to merger agreements, inaccurate developments and/or financial projections.
Oct 14, 2019 06:00 am ET
Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®
MADISON, Wis., Oct. 14, 2019 /PRNewswire/ -- (NASDAQ: EXAS) – Exact Sciences Corp. today announced that, in collaboration with Mayo Clinic, it has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. Voyage is a prospective, observational study designed to enroll more than 150,000 people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes. Voyage is one of the largest prospective, observational colorectal cancer screening studies ever conducted.
Oct 08, 2019 06:00 am ET
Exact Sciences schedules third-quarter 2019 earnings call
MADISON, Wis., Oct. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third-quarter 2019 financial results after the close of the U.S. financial markets on Oct. 29, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Sep 23, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Exact Sciences, Plus Therapeutics, or Arcadia Biosciences?
NEW YORK, Sept. 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, EXAS, PSTV, and RKDA.
Sep 23, 2019 05:45 am ET
Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
MADISON, Wis., Sept. 23, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older. The decision comes at a critical time when the incidence of colorectal cancer is on the rise among American adults under the age of 50.[i]
Sep 19, 2019 08:35 am ET
Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE
MADISON, Wis., Sept. 19, 2019 /PRNewswire/ -- Exact Sciences is a member of the 2019 Best Workplaces for Women list, an honor given by Great Place to Work® and FORTUNE to employers providing supportive, inclusive workplaces. To determine the Best Workplaces for Women, Great Place to Work® analyzed anonymous survey feedback representing more than 4.6 million employees at Great Place to Work-CertifiedTM organizations. Employees responded to more than 60 survey questions anonymously rating their employers.  
Sep 10, 2019 06:00 am ET
Cologuard® Helps More People Get Screened In A Cost-Effective Way
MADISON, Wis., Sept. 10, 2019 /PRNewswire/ -- (NASDAQ: EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those tested being previously unscreened.  Not only is Cologuard increasing the number of screened Americans, peer reviewed data shows that Cologuard is a cost-effective alternative for people at average risk for colorectal cancer (CRC).
Aug 30, 2019 09:15 am ET
Exact Sciences to participate in September investor conference
MADISON, Wis., Aug. 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.
Aug 02, 2019 05:18 pm ET
GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Genomic Health, Inc. (NasdaqGS: GHDX) to Exact Sciences Corp. (NasdaqGS: EXAS).  Under the terms of the proposed transaction, shareholders of Genomic will receive only $27.50 in cash and the equivalent of $44.50 in shares of Exact Sciences for each share of Genomic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the co
Aug 02, 2019 06:00 am ET
Exact Sciences to participate in August investor conference
MADISON, Wis., Aug. 2, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.
Jul 29, 2019 08:00 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection with the proposed acquisition of the Company by Exact Science Corp. ("EXAS") (NASDAQ: EXAS).  Under the terms of the agreement, Genomic Health shareholders will receive $27.50 in cash and $44.50 in EXAS shares for each GHDX share held, representing consideration of $72.00 per GHDX share. 
Jul 29, 2019 02:42 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Genomic Health, Inc. (“Genomic Health” or the “Company”) (NASDAQGS: GHDX) stock prior to July 29, 2019. You are hereby notified that...
Jul 29, 2019 07:01 am ET
Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000
MADISON, Wis., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $199.9 million and screened approximately 415,000 people with Cologuard during the quarter ended June 30, 2019. Second-quarter 2019 revenue and test volume grew 94 percent and 93 percent, respectively, from the same period of 2018.
Jul 29, 2019 07:00 am ET
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and Genomic Health, Inc. (NASDAQ: GHDX) today announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to be completed by the end of 2019.
Jul 17, 2019 06:00 am ET
Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019
MADISON, Wis., July 17, 2019 /PRNewswire/ -- The more than 2,400 people of Exact Sciences work every day to create life-changing innovations in earlier cancer detection. In the process, they also created a certifiably great place to work.
Jul 09, 2019 06:00 am ET
Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls
MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results.
May 20, 2019 08:56 am ET
Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
May 17, 2019 05:30 am ET
Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes.
May 01, 2019 06:00 am ET
Exact Sciences to participate in May investor conferences
MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.
Apr 30, 2019 04:05 pm ET
First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
MADISON, Wis., April 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $162.0 million and screened approximately 334,000 people with Cologuard during the quarter ended March 31, 2019. First-quarter 2019 revenue and test volume both grew 79 percent from the same period of 2018.
Apr 08, 2019 06:00 am ET
Exact Sciences schedules first-quarter 2019 earnings call
MADISON, Wis., Apr. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Mar 19, 2019 08:00 am ET
Kathleen Sebelius Appointed to Exact Sciences Board
MADISON, Wis., March 19, 2019 /PRNewswire/ -- Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services (HHS) from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (Nasdaq: EXAS), a leader in detecting cancer at its earliest, most treatable stages.
Mar 05, 2019 11:14 pm ET
Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027
MADISON, Wis., March 6, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount.  The Company has granted the underwriter a 30-day option to purchase up to an additional $97.5 million aggregate principal amount of the Notes solely to cover over-allotments, if any.
Mar 05, 2019 03:01 pm ET
Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027
MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes.  Concurrently with this offering, in separate transactions, the Company also
Mar 04, 2019 07:00 am ET
Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst R
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eaton Corporation, PLC (NYSE:ETN), Kite Realty Group Trust (NYSE:KRG),...
Mar 01, 2019 05:00 am ET
Exact Sciences to participate in March investor conferences
MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.
Feb 27, 2019 05:00 am ET
Cologuard Helps Screen Two Million People for Colorectal Cancer
MADISON, Wis., Feb. 27, 2019 /PRNewswire/ -- In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the groundbreaking product with Mayo Clinic, processed more than one million Cologuard tests in the last year alone. Nearly half of the people screened with Cologuard had not previously been screened for colorectal cancer, the second leading cause of cancer death in the United States.i
Feb 21, 2019 03:05 pm ET
Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard
MADISON, Wis., Feb. 21, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $454.5 million and completed approximately 934,000 Cologuard tests during the year ended Dec. 31, 2018. Full-year 2018 revenue and Cologuard test volume grew 71 percent and 64 percent from 2017, respectively.
Feb 20, 2019 04:06 pm ET
Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors
CUTERA, INC., (Nasdaq: CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced today the appointment of two new independent members to its Board of...
Feb 04, 2019 05:00 am ET
Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
MADISON, Wis., Feb. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Feb. 21, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Jan 28, 2019 07:30 am ET
Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolida
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rollins, Inc. (NYSE:ROL), Hospitality Properties Trust (NASDAQ:HPT), Exact...
Jan 06, 2019 06:00 pm ET
Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018
MADISON, Wis., Jan. 6, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $142.5 million and $143.5 million for the fourth quarter ended Dec. 31, 2018, an increase of 64 percent from the same quarter of 2017. The company completed approximately 292,000 Cologuard tests during the fourth quarter of 2018, which represents 66-percent growth from the same period of 2017.
Dec 20, 2018 05:00 am ET
Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Dec. 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.
Nov 09, 2018 05:00 am ET
Exact Sciences to participate in two November investor conferences
MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast.
Nov 05, 2018 07:25 am ET
Report: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Develop
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MRC Global Inc. (NYSE:MRC), Exact Sciences Corporation (NASDAQ:EXAS),...
Oct 30, 2018 04:05 pm ET
Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter
MADISON, Wis., Oct. 30, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $118.3 million and screened approximately 241,000 people with Cologuard during the quarter ended September 30, 2018. Third-quarter 2018 revenue and Cologuard test volume grew by 63 percent and 49 percent, respectively, from the same period of 2017.
Oct 18, 2018 07:00 am ET
Exact Sciences Strengthens Pipeline Capabilities with Acquisition of Biomatrica, a Leading Provider of Biological Sample Preservation Technology
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica's proprietary technolog
Oct 08, 2018 06:00 am ET
Exact Sciences schedules third-quarter 2018 earnings call
MADISON, Wis., Oct. 8, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third-quarter 2018 financial results after the close of the U.S. financial markets on Oct. 30, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Oct 04, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Ashland Global, Pattern Energy Group, Jacobs Engineering Group, Olin, Exact Sciences, and Comcast — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Pattern Energy Group Inc....
Aug 31, 2018 06:00 am ET
Exact Sciences to participate in September investor conferences
MADISON, Wis., Aug. 31, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during September and invited investors to participate by webcast.
Aug 22, 2018 06:15 am ET
Exact Sciences to host conference call and webcast to discuss its Cologuard co-promotion agreement with Pfizer
MADISON, Wis., Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will host a conference call and webcast on Wednesday, Aug. 22, 2018, at 8:00 a.m. ET to discuss details of its co-promotion agreement with Pfizer. Kevin Conroy, the company's chairman and CEO; Jeff Elliott, chief financial officer; and Mark Stenhouse, president, Cologuard, will make remarks and take questions on the call. Nick Lagunowich, regional president North America, Pfizer Internal Medicine, will also make remarks on the call.
Aug 22, 2018 06:00 am ET
Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®
MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Pfizer Inc. (NYSE: PFE) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact Sciences' sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign.  
Aug 13, 2018 09:00 am ET
Green Bay Packers and Cologuard Launch "Crossing the 50" Colon Cancer Awareness Campaign
GREEN BAY, Wis. and MADISON, Wis., Aug. 13, 2018 /PRNewswire/ -- When the Green Bay Packers cross the 50-yard line this season, it will be meaningful both on and off the field.
Aug 06, 2018 06:00 am ET
Exact Sciences to participate in Canaccord Genuity Growth Conference
MADISON, Wis., Aug. 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference during August and invited investors to participate by webcast.
Aug 02, 2018 11:00 am ET
Tom Lehman Joins Forces with Fight Colorectal Cancer to Raise Awareness of Nation's Second-Leading Cause of Cancer Deaths
BLAINE, Minn., Aug. 2, 2018 /PRNewswire/ -- Longtime PGA TOUR professional and colon cancer survivor, Tom Lehman, is teaming up with Fight Colorectal Cancer (Fight CRC) to help raise awareness of the nation's second-deadliest cancer. The one-year agreement, supported by Exact Sciences (NASDAQ: EXAS), will feature Lehman wearing the Fight CRC logo on his hat, numerous public appearances, and a public service announcement campaign highlighting the importance of early detection and the options available for colon cancer screening, including accurate, non-invasive options.
Aug 01, 2018 04:05 pm ET
Cologuard® revenue increased 78 percent to $103 million during second quarter
MADISON, Wis., Aug. 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $102.9 million and completed approximately 215,000 Cologuard tests during the quarter ended June 30, 2018. Second-quarter 2018 revenue and Cologuard test volume grew by 78 percent and 59 percent, respectively, from the same period of 2017.
Jul 09, 2018 04:15 pm ET
Exact Sciences to host annual meeting, second-quarter 2018 results webcasts and calls
MADISON, Wis., July 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and to discuss its second-quarter 2018 financial results.
Jun 26, 2018 11:00 am ET
Nurse Practitioners are Critical Source of Colorectal Cancer Screening Information for Patients, Survey Shows
MADISON, Wis., June 26, 2018 /PRNewswire/ -- Exact Sciences today announced results of HealthyWomen's National Colorectal Cancer SNAPP (Screening KNowledge and Practice Patterns) Survey, in partnership with the American Association of Nurse Practitioners (AANP). This survey of 358 nurse practitioners (NPs) showed they are highly engaged in colorectal cancer (CRC) screening, both personally and on behalf of their patients. It also revealed the need for increased awareness of the multitarget stool DNA test, a recommended CRC screening option.
Jun 26, 2018 07:40 am ET
Research Report Identifies PDL BioPharma, TEGNA, Patterson Companies, Boardwalk Pipeline Partners, Exact Sciences, and Berkshire Hathaway with Renewed Outlook — Fundamental Analysis, Calculating Forwa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDL BioPharma, Inc. (NASDAQ:PDLI), TEGNA Inc. (NYSE:TGNA), Patterson...
Jun 19, 2018 09:00 am ET
Cologuard Challenge Expands to AmFam Championship Urging PGA TOUR Champions Fans to Get Screened for Colon Cancer
MADISON, Wis., June 19, 2018 /PRNewswire/ -- The national colon cancer screening movement led by golfer Jerry Kelly will be front and center when the PGA TOUR Champions comes to University Ridge Golf Course June 22-24, 2018 for the American Family Insurance Championship (AmFam Championship).
Jun 08, 2018 08:00 am ET
Exact Sciences Announces Upsizing and Pricing of 1.0% Convertible Senior Notes Due 2025
MADISON, Wis., June 8, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) announced today that it has priced its underwritten public offering of 1.0% Convertible Senior Notes due 2025 (the "Notes") and upsized the offering from $150 million to $190 million aggregate principal amount, providing for total gross proceeds of $202.4 million, excluding accrued interest.  The initial public offering price for the Notes will be 106.5% of face value plus accrued interest from January 17, 2018.  The Notes issuance is a reopening of, and will be fully fungible and form a single series with,
Jun 07, 2018 04:01 pm ET
Exact Sciences Announces Offering of 1.0% Convertible Senior Notes Due 2025
MADISON, Wis., June 7, 2018 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) today announced an underwritten public offering of $150 million aggregate principal amount of its 1.0% convertible senior notes due 2025 (the "Notes") in a registered public offering. The Company also plans to grant to the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest. The Notes issuance is a reopening of, and will be part of the same series as, the $690 mi
Jun 05, 2018 04:30 pm ET
Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma
WASHINGTON, June 5, 2018 /PRNewswire/ -- Researchers at Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in the liver.1 The researchers detailed their findings during a presentation today at Digestive Disease Week, the world's largest gathering of gastroenterologists and scientists in the field.
Jun 01, 2018 06:00 am ET
Exact Sciences to participate in June investor conferences
MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during June and invited investors to participate by webcast.
May 08, 2018 07:20 am ET
Recent Analysis Shows Boardwalk Pipeline Partners, Chegg, CommScope Holding, Exact Sciences, HollyFrontier, and Hecla Mining Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Boardwalk Pipeline Partners L.P. (NYSE:BWP), Chegg, Inc. (NYSE:CHGG),...
May 03, 2018 09:00 am ET
Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer
MILWAUKEE and MADISON, Wis., May 3, 2018 /PRNewswire/ -- Colon cancer cut short the life of legendary football coach Vince Lombardi at the age of 57 and, nearly 50 years later, remains the number two cancer killer in the United States. Now, the foundation bearing his name and one of the country's premier cancer diagnostics companies are teaming up to fight back.
May 01, 2018 06:00 am ET
Exact Sciences to participate in two investor conferences during May
MADISON, Wis., May 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during May and invited investors to participate by webcast.
Apr 30, 2018 09:30 am ET
Must See Stock Score Reports for Charter Communications, Exact Sciences, Nike, Sprint, and Snap Inc.
CHICAGO, April 30, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHTR, EXAS, NKE, S, and SNAP.
Apr 26, 2018 04:05 pm ET
Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000
MADISON, Wis., April 26, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $90.3 million and completed approximately 186,000 Cologuard tests during the quarter ended Mar. 31, 2018. First-quarter 2018 revenue and Cologuard test volume both grew 87 percent from 2017.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.